Trial reportTranslational vision science & technology2026
Prognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON.
Trial report in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify factors influencing best corrected visual acuity (BCVA) prognosis in patients with AQP4-IgG+ neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) after treating with high-dose intravenous methylprednisolone. Methods: A total of 161 intravenous methylprednisolone (IVMP)-treated patients were randomized into training (n = 113) and internal validation (n = 48) sets at a ratio of 7:3. Using Least Absolute Shrinkage and Selection Operator regression, 16 candidate predictors were screened to construct a logistic model to predict follow-up BCVA after six months post-ON attack. Discrimination (area under curve [AUC]), calibration, and clinical net benefit (decision curve analysis [DCA]) were assessed. Results: The final model included seven predictors: age, AQP4-IgG titer, non-ON attack history, baseline BCVA, mean deviation, macular ganglion cell inner plexiform layer thickness, and treatment window. AUCs were 0.904 (95% confidence interval [CI], 0.850-0.959) and 0.864 (95% CI, 0.761-0.967) in training and validation sets, respectively. Calibration curves indicated high consistency, and DCA demonstrated significant net benefit at 10%-90% risk thresholds. Conclusions: The validated prediction model effectively stratifies IVMP-treated patients at risk of visual disability, enabling precision management. Translational Relevance: By converting heterogeneous prognostic factors into a practical prediction tool, this work empowers clinicians to deliver precision care for a blinding complication of NMOSD, directly reducing preventable visual disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.